Cargando…

Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer

BACKGROUND: Adjuvant endocrine therapy undoubtedly prolongs the time to recurrence for patients with hormone-positive early breast cancer. Extended endocrine therapy to 10 years or longer has been expected to bring a greater clinical advantage. However, the related research conclusions are controver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Li, Chang, Bingmei, Jiang, Xiaoyue, Fan, Xueke, Li, Yingrui, Li, Teng, Wu, Shanshan, Zhang, Jun, Kariminia, Seyed, Li, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186070/ https://www.ncbi.nlm.nih.gov/pubmed/30314452 http://dx.doi.org/10.1186/s12885-018-4878-4

Ejemplares similares

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer
por: Hu, Ruyi, et al.
Publicado: (2021)

Completion of 5-year adjuvant endocrine therapy in the community
por: Makubate, B, et al.
Publicado: (2010)

PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy
por: Fan, Yu, et al.
Publicado: (2022)

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
por: Ribi, K, et al.
Publicado: (2012)

DNT Cell-based Immunotherapy: Progress and Applications
por: Li, Yingrui, et al.
Publicado: (2020)

Extending Adjuvant Endocrine Therapy for 10 Years: A Mixed-Methods Analysis of Women’s Decision Making in an Online Breast Cancer Forum
por: Eraso, Yolanda, et al.
Publicado: (2021)

Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor
por: Jiang, Xiaoyue, et al.
Publicado: (2019)

Characteristics and prognostic values of traditional pathological parameters and advanced molecular subtypes in women in Beijing with operable breast cancer: a retrospective analysis
por: Li, Qin, et al.
Publicado: (2018)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

A Nation-Wide Multicenter 10-Year (1999-2008) Retrospective Clinical Study of Endocrine Therapy for Chinese Females with Breast Cancer
por: Zhou, Can, et al.
Publicado: (2014)

The Christie hospital adjuvant tamoxifen trial--status at 10 years.
por: Ribeiro, G., et al.
Publicado: (1988)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo, Qin-Guo, et al.
Publicado: (2016)

Beliefs about medicines and adherence in women with breast cancer on adjuvant endocrine therapy
por: Tan, Eng Hooi, et al.
Publicado: (2021)

Relationship between renal and liver function with diabetic retinopathy in patients with type 2 diabetes mellitus: a study based on cross-sectional data
por: Yao, Xi, et al.
Publicado: (2022)

Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review
por: Yussof, Izzati, et al.
Publicado: (2022)

Etiology of precocious puberty, 10 years study in Endocrine Reserch Centre (Firouzgar), Tehran
por: Rohani, Farzaneh, et al.
Publicado: (2012)

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial
por: Ohashi, Yasuo, et al.
Publicado: (2017)

Improved disease-free survival with adjuvant radiotherapy in early-stage endometrial cancer: 10-year outcome analysis
por: Arslan, Suheyla Aytac, et al.
Publicado: (2020)

ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy
por: Song, Fangbin, et al.
Publicado: (2017)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
por: Bekes, Inga, et al.
Publicado: (2023)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2022)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

Long-term oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer: Systemic review and meta-analysis of 5-year and 10-year follow-up data
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)

Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience
por: Brunello, Antonella, et al.
Publicado: (2015)

Adjuvant therapy for high‐risk cutaneous squamous cell carcinoma: 10‐year review
por: Newman, Jason G., et al.
Publicado: (2021)

Comparison of female rat reproductive effects of pubertal versus adult exposure to known endocrine disruptors
por: Boberg, Julie, et al.
Publicado: (2023)

Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression
por: Wei, Yuhan, et al.
Publicado: (2022)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
por: Davies, Christina, et al.
Publicado: (2013)

Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform
por: Eom, Kirsten Y., et al.
Publicado: (2021)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis
por: He, Tao, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
por: Gomaa, Sameh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j7pgdmlo4r5005qjqq1bhrpaat